Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers

Epilepsia

Volumn 52, Issue 7, 2011, Pages 1351-1358

  Bullman, Jonathan ^a   Nicholls, Andrew ^a   Van Landingham, Kevan ^b   Fleck, Richard ^b   Vuong, Alain ^b   Miller, James ^b   Alexander, Sarah ^a   Messenheimer, John ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Epilepsy; Lamotrigine; Pharmacokinetics

Indexed keywords

ATORVASTATIN; LAMOTRIGINE; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PHENYTOIN; PYRROLES; TRIAZINES;

EID: 79959982280     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03118.x     Document Type: Article

References (22)

1. Amsden GW, Kuye O, Wei GC,. (2002) A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol 42: 444-449. (Pubitemid 34259779)
2. Biton V,. (2006) Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2: 1009-1018. (Pubitemid 44911544)
3. Diaz RA, Sancho J, Serratosa J,. (2008) Antiepileptic drugs interactions. Neurologist 14 (6 Suppl. 1): S55-S65.
4. Garnett WR,. (1997) Lamotrigine: pharmacokinetics. J Child Neurol 12 (Suppl. 1): S10-S15. (Pubitemid 28084004)
5. Gidal BE, French JA, Grossman P, Le Teuff G,. (2009) Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 72: 419-425.
6. Hauser WA, Annegers JF, Rocca WA,. (1996) Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71: 576-586.
7. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U,. (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-coa reductase inhibitor atorvastatin. Drug Metab Dispos 28: 1369-1378.
8. Kantola T, Kivisto KT, Neuvonen PJ,. (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64: 58-65. (Pubitemid 28377331)
9. Kapur NK, Musunuru K,. (2008) Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 4: 341-353. (Pubitemid 351711963)
10. Khandwala HM,. (2006) Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin. South Med J 99: 1385-1387. (Pubitemid 46035558)
11. Lamictal XR. (2009) (lamotrigine) extended-release tablets prescribing information. GlaxoSmithKline, May 2009. Available at:. Accessed on 5 January 2010.
12. Lipitor. (2009) (atorvastatin calcium) prescribing information. Pfizer, June 2009. Available at:. Accessed on 5 January 2010.
13. Murphy MJ, Dominiczak MH,. (1999) Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 75: 359-360. (Pubitemid 29237982)
14. Neuvonen PJ, Niemi M, Backman JT,. (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565-581. (Pubitemid 44908269)
15. Patsalos PN, Froscher W, Pisani F, van Rijn CM,. (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43: 365-385. (Pubitemid 34297175)
16. Perucca E,. (2005) Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61: 246-255.
17. Raofi S, Schappert SM,. (2006) Medication therapy in ambulatory medical care: United States, 2003-04. National Center for Health Statistics. Vital Health Stat 13: 1-40.
18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ,; JUPITER Study Group. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.
19. Spatz ES, Canavan ME, Desai MM,. (2009) From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2: 41-48.
20. Tan KM, Kelly JG, McGarry K,. (2007) Statins and phenytoin interaction-a case history. Br J Clin Pharmacol 65: 147-148.
21. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjorndal T,. (2004) Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59: 879-882. (Pubitemid 38333678)
22. Williams D, Feely J,. (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41: 343-370. (Pubitemid 34713089)